{"id":41962,"date":"2025-09-22T14:54:33","date_gmt":"2025-09-22T06:54:33","guid":{"rendered":"https:\/\/flcube.com\/?p=41962"},"modified":"2025-09-22T14:54:34","modified_gmt":"2025-09-22T06:54:34","slug":"innovent-secures-2nd-nmpa-approval-for-mazdutide-first-dual-glp%e2%80%911-gcgr-therapy-for-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41962","title":{"rendered":"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\/GCGR Therapy for Type\u202f2 Diabetes"},"content":{"rendered":"\n<p><strong>Innovent Biologics Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) announced that its <strong>mazdutide<\/strong> injection (IBI362) has received its second approval from China\u2019s National Medical Products Administration (NMPA). The new indication authorizes use for glycemic control in adults with type\u202f2 diabetes, making mazdutide the world\u2019s first glucagon\/GLP\u20111 dual\u2011receptor agonist approved for this purpose.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-mazdutide-brings-to-the-diabetes-landscape\">What Mazdutide Brings to the Diabetes Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual\u2011Mechanism Action<\/strong> \u2013 As a mammalian oxyntomodulin (OXM) analog, mazdutide simultaneously activates the <strong>GLP\u20111 receptor<\/strong> (promoting insulin secretion and lowering blood glucose) and the <strong>GCGR<\/strong> (boosting energy expenditure, weight loss, and liver fat metabolism).<\/li>\n\n\n\n<li><strong>Complementary to Lifestyle<\/strong> \u2013 The drug is intended as an adjunct to a reduced\u2011calorie diet and increased physical activity, aligning with current diabetes management guidelines.<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class<\/strong> \u2013 No other therapy combines these two pathways for diabetes treatment, offering a unique therapeutic option for patients who struggle to achieve glycemic targets with existing monotherapies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-milestones-in-the-chinese-market\">Milestones in the Chinese Market<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>June\u202f2025<\/strong> \u2013 First NMPA approval for long\u2011term weight management in adults.<\/li>\n\n\n\n<li><strong>September\u202f2025<\/strong> \u2013 Second approval for type\u20112 diabetes glycemic control.<\/li>\n\n\n\n<li><strong>Strategic Implications<\/strong> \u2013 The dual indication expands Innovent\u2019s revenue base and positions the company to capture a sizable share of the rapidly growing Chinese diabetes market, projected to exceed <strong>US$20\u202fbillion<\/strong> by 2030.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-co-development-and-future-outlook\">Co\u2011Development and Future Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Partnership<\/strong> \u2013 Mazdutide was co\u2011developed with <strong>Eli\u202fLilly &amp; Co.<\/strong>, leveraging Lilly\u2019s global development expertise.<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong> \u2013 Innovent plans to pursue additional indications for mazdutide, including non\u2011alcoholic steatohepatitis (NASH) and obesity, in line with its broader OXM\u2011based platform.<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong> \u2013 With two consecutive NMPA approvals, Innovent is well\u2011positioned to seek expedited FDA review, potentially accelerating global launch.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41964,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,910,198,15],"class_list":["post-41962","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-hkg-1801","tag-innovent-biologics","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\/GCGR Therapy for Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second approval from China\u2019s National Medical Products Administration (NMPA). The new indication authorizes use for glycemic control in adults with type\u202f2 diabetes, making mazdutide the world\u2019s first glucagon\/GLP\u20111 dual\u2011receptor agonist approved for this purpose.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41962\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\/GCGR Therapy for Type\u202f2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second approval from China\u2019s National Medical Products Administration (NMPA). The new indication authorizes use for glycemic control in adults with type\u202f2 diabetes, making mazdutide the world\u2019s first glucagon\/GLP\u20111 dual\u2011receptor agonist approved for this purpose.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41962\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-22T06:54:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-22T06:54:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\\\/GCGR Therapy for Type\u202f2 Diabetes\",\"datePublished\":\"2025-09-22T06:54:33+00:00\",\"dateModified\":\"2025-09-22T06:54:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962\"},\"wordCount\":287,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2203.webp\",\"keywords\":[\"Diabetes\",\"HKG: 1801\",\"Innovent Biologics\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41962#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41962\",\"name\":\"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\\\/GCGR Therapy for Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2203.webp\",\"datePublished\":\"2025-09-22T06:54:33+00:00\",\"dateModified\":\"2025-09-22T06:54:34+00:00\",\"description\":\"Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second approval from China\u2019s National Medical Products Administration (NMPA). The new indication authorizes use for glycemic control in adults with type\u202f2 diabetes, making mazdutide the world\u2019s first glucagon\\\/GLP\u20111 dual\u2011receptor agonist approved for this purpose.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41962\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\\\/GCGR Therapy for Type\u202f2 Diabetes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41962#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\\\/GCGR Therapy for Type\u202f2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\/GCGR Therapy for Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second approval from China\u2019s National Medical Products Administration (NMPA). The new indication authorizes use for glycemic control in adults with type\u202f2 diabetes, making mazdutide the world\u2019s first glucagon\/GLP\u20111 dual\u2011receptor agonist approved for this purpose.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41962","og_locale":"en_US","og_type":"article","og_title":"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\/GCGR Therapy for Type\u202f2 Diabetes","og_description":"Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second approval from China\u2019s National Medical Products Administration (NMPA). The new indication authorizes use for glycemic control in adults with type\u202f2 diabetes, making mazdutide the world\u2019s first glucagon\/GLP\u20111 dual\u2011receptor agonist approved for this purpose.","og_url":"https:\/\/flcube.com\/?p=41962","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-22T06:54:33+00:00","article_modified_time":"2025-09-22T06:54:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41962#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41962"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\/GCGR Therapy for Type\u202f2 Diabetes","datePublished":"2025-09-22T06:54:33+00:00","dateModified":"2025-09-22T06:54:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41962"},"wordCount":287,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41962#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2203.webp","keywords":["Diabetes","HKG: 1801","Innovent Biologics","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41962#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41962","url":"https:\/\/flcube.com\/?p=41962","name":"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\/GCGR Therapy for Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41962#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41962#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2203.webp","datePublished":"2025-09-22T06:54:33+00:00","dateModified":"2025-09-22T06:54:34+00:00","description":"Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second approval from China\u2019s National Medical Products Administration (NMPA). The new indication authorizes use for glycemic control in adults with type\u202f2 diabetes, making mazdutide the world\u2019s first glucagon\/GLP\u20111 dual\u2011receptor agonist approved for this purpose.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41962#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41962"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41962#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2203.webp","width":1080,"height":608,"caption":"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\/GCGR Therapy for Type\u202f2 Diabetes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41962#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Secures 2nd NMPA Approval for Mazdutide \u2013 First Dual GLP\u20111\/GCGR Therapy for Type\u202f2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41962"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41962\/revisions"}],"predecessor-version":[{"id":41965,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41962\/revisions\/41965"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41964"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}